We are live on ! Find out more

Ascendis Pharma A/S

ASND

Market cap $17.1B

164 hedge funds and large institutions have $6.54B invested in Ascendis Pharma A/S in 2023 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 58 increasing their positions, 65 reducing their positions, and 37 closing their positions.

New

Increased

Maintained

Reduced

Closed

413% more call options, than puts

Call options by funds: $117M | Put options by funds: $22.8M

8.86% less ownership

Funds ownership: 115.61% → 106.75% (-8.9%)

11% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 65

12% less funds holding

Funds holding: 187 → 164 (-23)

19% less capital invested

Capital invested by funds: $8.05B → $6.54B (-$1.51B)

35% less funds holding in top 10

Funds holding in top 10: 20 → 13 (-7)

57% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 37

Holders

164

Holders Change

-23

Holders Change %

-12.3%

% of All Funds

2.61%

Holding in Top 10

Holding in Top 10 Change

-7

Holding in Top 10 Change %

-35%

% of All Funds

0.21%

New

Increased

Reduced

Closed

Calls

$117M

Puts

$22.8M

Net Calls

+$94.2M

Net Calls Change

+$7.85M

Top Buyers

1	T. Rowe Price Investment Management Baltimore, Maryland	+$73.8M
2	Capital International Investors Los Angeles, California	+$48.2M
3	Point72 Asset Management Stamford, Connecticut	+$45.3M
4	ACA Avoro Capital Advisors New York	+$25.7M
5	WP Woodline Partners San Francisco, California	+$24M

Top Sellers

1	BBA Baker Bros. Advisors New York	-$605M
2	DTC Deep Track Capital Greenwich, Connecticut	-$85.5M
3	T. Rowe Price Associates Baltimore, Maryland	-$38.9M
4	Adage Capital Partners Boston, Massachusetts	-$16M
5	Citadel Advisors Miami, Florida	-$15.5M

#	Name	Holding	Trade Value	Shares Change	Change in Stake
76	WBC 76 Westpac Banking Corp Sydney, Australia	$2.91M	-$1.1M	-9,614	-26%
77	HJIM 77 Henry James International Management New York	$2.79M	-$686	-6	-0%
78	SSA 78 Schonfeld Strategic Advisors New York	$2.24M	-$5.37M	-46,958	-69%
79	79 DekaBank Deutsche Girozentrale Frankfurt, Germany	$2.15M	–	–	–
80	TA 80 Tamarack Advisers Carlsbad, California	$2.14M	-$2.86M	-25,000	-56%
81	81 Bank of America Charlotte, North Carolina	$2.14M	-$1.12M	-9,817	-33%
82	EAM 82 Erste Asset Management Vienna, Austria	$2.01M	–	–	–
83	PL 83 Parkwood LLC Cleveland, Ohio	$2M	+$129K	+1,125	+6%
84	84 Mirae Asset Global Investments Seoul, South Korea	$1.81M	-$326K	-2,847	-14%
85	85 State of Wisconsin Investment Board Madison, Wisconsin	$1.58M	-$72.4K	-633	-4%
86	86 Jane Street New York	$1.54M	-$4.41M	-38,560	-73%
87	87 PNC Financial Services Group Pittsburgh, Pennsylvania	$1.48M	+$175K	+1,526	+12%
88	BCP 88 Berylson Capital Partners Boston, Massachusetts	$1.46M	+$1.56M	+13,600	New
89	89 Balyasny Asset Management Chicago, Illinois	$1.44M	-$4.59M	-40,103	-75%
90	90 Nomura Asset Management Tokyo, Japan	$1.43M	+$74.1K	+648	+5%
91	91 Jennison Associates New York	$1.4M	-$66.4K	-580	-4%
92	JMPWA 92 JP Morgan Private Wealth Advisors San Francisco, California	$1.39M	-$11.9M	-104,394	-89%
93	93 CAPTRUST Financial Advisors Raleigh, North Carolina	$1.32M	–	–	–
94	CWA 94 CM Wealth Advisors Beachwood, Ohio	$1.32M	+$1.97M	+17,254	New
95	HCA 95 Harbor Capital Advisors Chicago, Illinois	$1.31M	-$115K	-1,009	-8%
96	96 Allianz Asset Management Munich, Germany	$1.2M	+$1.28M	+11,200	New
97	97 Wells Fargo San Francisco, California	$1.15M	-$3.2K	-28	-0.3%
98	ETCM 98 Evolutionary Tree Capital Management Alexandria, Virginia	$1.14M	-$1.34M	-11,695	-52%
99	99 Stifel Financial St. Louis, Missouri	$983K	-$23.5K	-205	-2%
100	100 Handelsbanken Fonder Stockholm, Sweden	$911K	+$160K	+1,400	+20%

ASND Hedge Fund Activity: Q1 2023 in Review

164 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2023, worth a combined $6.54B — down 19% from $8.05B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of ASND and 16 opened new positions — a net loss of 21 holders — while 65 trimmed existing stakes and 58 added.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $73.8M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $605M sold.

164 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2023, down from 187 in Q4 2022.
Funds reported $6.54B of Ascendis Pharma A/S stock for Q1 2023, down 19% quarter-over-quarter.
16 funds opened new Ascendis Pharma A/S positions in Q1 2023 and 37 closed out, a net change of -21 holders.
The largest Ascendis Pharma A/S buyer in Q1 2023 was T. Rowe Price Investment Management, an estimated $73.8M added.
The largest Ascendis Pharma A/S seller in Q1 2023 was Baker Bros. Advisors, an estimated $605M sold.

Based on aggregated 13F filings for Q1 2023.

Ascendis Pharma A/S ASND Market cap $17.1B